Direct medical cost of Crohn's disease in Spain;Costes médicos directos de la enfermedad de Crohn en España

Pharmacoeconomics - Spanish Research Articles

Volumn 7, Issue 1, 2010, Pages 38-46

  Casellas, F ^a   Panes J ^b   Garcia Sanchez V ^c   Ginard, D ^d   Gomollon F ^e   Hinojosa, J ^f   Marin Jimenez I ^g   Barreiro, M ^h   Bastida, G ⁱ   Lindner, Leandro ^j   Gimenez E ^j   Vieta, A ^j  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL SON DURETA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL DE SAGUNTO   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h University Hospital of Santiago de Compostela   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j IQVIA   (United States)

more..

Author keywords

Biological therapy; Cost of illness; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COST OF ILLNESS; CROHN DISEASE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPAIN;

EID: 77953119100     PISSN: 1695405X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320866     Document Type: Article

References (20)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007:369(9573):1641-1657 (Pubitemid 46722637)
2. Shanahan, F. Crohn's disease. Lancet 2002;359(9300):62-69.
3. Vucelic B, Korac B, Sentic M, Milicic D, Hadzic N, Juresa V, Bozikov J, Rotkvic I, Buljevac M, Kovacevic I, et al. Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. Int J Epidemiol. 1991 Mar;20(1):216-20.
4. Kyle J. Crohn's disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology. 1992; 103(2):392-399
5. Rodrigo L, Riestra S, Nino P, Cadahia V, Tojo R, Fuentes D, Moreno M, Gonzalez Ballina E, Fernandez E. A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain) Rev Esp Enferm Dig. 2004 May;96(5):296-305.
6. Trallori G, Palli D, Saieva C, Bardazzi G, Bonanomi AG, d'Albasio G, Galli M, Vannozzi G, Milla M, Tarantino O, Renai F, Messori A, Amorosi A, Pacini F, Morettini A population-based study of inflammatory bowel disease in Florence over 15 years (1978-1992). A Scand J Gastroenterol. 1996 Sep;31(9):892-899
7. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol. 2006 Jan 7;12(1):75-81.
8. American Gastroenterological Association Institute. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939.
9. Lichenstein GR, Abreu MT, Cohen R et al. American Gastroenterological Association Institute. American Gastroenterologicasl Association Institute medical position statement on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939.
10. Silverstein M, Loftus E, Sandborn W, Tremaine W, Feagan B, Nietert P et al. Clinical course and costs of care for Crohn's Disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57. (Pubitemid 29297619)
11. Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis. 2003 Dec;35(12):853-861
12. Jaisson-Hot I, Flourié B, Descos L et al. Management for severe Crohn's disease: a lifetime cost-utility analysis. Intl. J. of technology assessment in health care 2004;20:274-279. (Pubitemid 39079562)
13. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes. 3th ed. London: Oxford Medical Publications, 2005
14. Ekbom A, Blomqvist P Cost to society of Crohn's disease. Research and clinical forum 1998; 20(3): 33-39. (Pubitemid 28562856)
15. a actualización. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2005.
16. Nomenclater. Colegio Oficial de Médicos de Barcelona; 2008.
17. Base de datos de costes sanitarios Esalud [database online]. Versión 2.2. Barcelona: Esalud; 2009. Updated January 1, 2009.
18. Institute Nacional de Estadística. Índice de precios de consume (Base 2006).¿ Cuanto ha variado el IPC desde...?. Available at : http://www.ine.es/cgi-bin/certi?L=0&PI=01&AI=2005&P F=01&AF=2008&TP=N. Accessed March 3, 2008.
19. EMEA. Humira - Summary of product characteristics. Disponible en URL : http://www.emea.europa.eu/humandocs/ PDFs/EPAR/humira/H-481-PI-en.pdf. Accessed March 3, 2008.
20. EMEA. Remicade - Summary of product characteristics. Disponible en URL : http://www.emea.europa.eu/humandocs/ PDFs/EPAR/Remicade/H-240-PI-en.pdf. Accessed March 3, 2008.